Augere Medical Secures $1.9 Million in Funding for Groundbreaking AI-based Polyp Detection System

Augere Medical, a pioneering Norwegian medical device company founded in 2018, has successfully raised $1,900,000 to advance its mission of revolutionizing colorectal cancer screening. Known for its innovative approach and commitment to quality, Augere Medical is at the forefront of developing the PolypAID System, which leverages cutting-edge Artificial Intelligence (AI) technology to enhance polyp detection rates during colonoscopy. The funding will be instrumental in further refining the PolypAID System, which analyzes real-time video streams to assist physicians in making informed decisions throughout the screening process. Collaborating closely with leading colonoscopists and the research team at Simula, Augere aims to drastically improve cancer detection while prioritizing patient care and transparency. The term "augere," meaning "to increase" in Latin, epitomizes the company’s goal to enhance medical outcomes and redefine the standards of care in cancer screening. By focusing on innovation, agility, and delivering substantial results, Augere Medical is determined to fulfill its vision of reducing the burden on patients while alleviating the financial strain on healthcare systems. This funding marks a pivotal step toward realizing their mission—making lives better through state-of-the-art AI solutions that enhance the detection and characterization of cancerous abnormalities. With the tagline "Confidence in outcomes™," Augere Medical stands ready to lead tangible change in the industry, ensuring that both physicians and patients have the tools they need for a healthier future.